Brokerages forecast that Tandem Diabetes Care Inc (NASDAQ:TNDM) will report ($0.08) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Tandem Diabetes Care’s earnings, with estimates ranging from ($0.21) to $0.06. Tandem Diabetes Care posted earnings per share of $0.02 in the same quarter last year, which would suggest a negative year over year growth rate of 500%. The business is expected to report its next earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($0.58) per share for the current year, with EPS estimates ranging from ($0.68) to ($0.41). For the next year, analysts expect that the company will report earnings of $0.02 per share, with EPS estimates ranging from ($0.30) to $0.50. Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Tandem Diabetes Care.
Several equities analysts recently issued reports on the company. UBS Group upgraded Tandem Diabetes Care from a “neutral” rating to a “buy” rating and set a $75.00 price target on the stock in a report on Friday, October 4th. BidaskClub upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating in a research report on Saturday, November 23rd. Guggenheim began coverage on shares of Tandem Diabetes Care in a research note on Thursday, October 17th. They issued a “buy” rating and a $76.00 target price on the stock. Finally, ValuEngine lowered shares of Tandem Diabetes Care from a “sell” rating to a “strong sell” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $75.31.
NASDAQ TNDM opened at $67.43 on Friday. The stock has a market capitalization of $4.08 billion, a P/E ratio of -26.44 and a beta of 0.23. Tandem Diabetes Care has a 52 week low of $29.43 and a 52 week high of $74.81. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.05 and a current ratio of 2.46. The stock has a fifty day moving average of $63.67 and a 200-day moving average of $64.16.
In other Tandem Diabetes Care news, EVP Brian B. Hansen sold 15,000 shares of Tandem Diabetes Care stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $62.01, for a total transaction of $930,150.00. Following the transaction, the executive vice president now directly owns 17,991 shares in the company, valued at $1,115,621.91. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John F. Sheridan sold 462 shares of Tandem Diabetes Care stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $70.00, for a total value of $32,340.00. Following the transaction, the chief executive officer now owns 2,963 shares in the company, valued at $207,410. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 45,000 shares of company stock valued at $2,988,036. 6.90% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Tandem Diabetes Care by 5.3% in the second quarter. Vanguard Group Inc. now owns 6,227,080 shares of the medical device company’s stock valued at $401,771,000 after buying an additional 316,123 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Tandem Diabetes Care by 2.1% in the second quarter. BlackRock Inc. now owns 4,054,911 shares of the medical device company’s stock valued at $261,622,000 after purchasing an additional 83,336 shares in the last quarter. TimesSquare Capital Management LLC lifted its holdings in shares of Tandem Diabetes Care by 9.0% in the third quarter. TimesSquare Capital Management LLC now owns 1,239,535 shares of the medical device company’s stock valued at $73,108,000 after purchasing an additional 102,758 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Tandem Diabetes Care by 15.9% during the second quarter. Renaissance Technologies LLC now owns 897,927 shares of the medical device company’s stock worth $57,934,000 after buying an additional 123,500 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Tandem Diabetes Care by 248.9% during the first quarter. FMR LLC now owns 705,789 shares of the medical device company’s stock worth $44,818,000 after buying an additional 503,482 shares in the last quarter. Institutional investors and hedge funds own 83.16% of the company’s stock.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
See Also: What defines an oversold asset?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.